Genzyme Corporation / ILEX Oncology Inc.

Chronic Lymphocytic Leukemia (CLL)

23K US cases/yr

Disease Overview

Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia in Western countries, characterized by the slow accumulation of mature, abnormal B-lymphocytes in blood, marrow, and lymph nodes. It primarily affects older adults (median age 71) and is incurable with conventional therapy, though many patients live for years with watchful-waiting management before requiring systemic treatment.

Competitive Landscape

At deal close in 2004, CLL therapy revolved around alkylator-based regimens (chlorambucil, cyclophosphamide) and the purine analog fludarabine, often combined with rituximab (Rituxan). Campath (alemtuzumab) — the asset Genzyme acquired via ILEX — was approved by the FDA in 2001 as a third-line option for fludarabine-refractory B-CLL, with a differentiated anti-CD52 mechanism that depleted both B and T lymphocytes. The deal gave Genzyme its first oncology marketed asset and a platform to expand Campath into front-line CLL and multiple sclerosis (later Lemtrada). The FTC required divestiture of Campath rights for solid-organ-transplant induction to Schering AG to preserve competition with Thymoglobulin. The CLL field has since been transformed by BTK inhibitors (Imbruvica, Calquence), BCL-2 inhibitor venetoclax (Venclexta), and PI3K inhibitors, displacing chemoimmunotherapy and ultimately leading Sanofi-Genzyme to withdraw Campath from oncology markets in 2012 to reposition it as Lemtrada in MS.